Barcelona, Spain: Prous Institute for Biomedical Research
(PIBR) has announced today a research collaboration with the Broad Institute of MIT and Harvard implementing novel computational target action prediction
methods to develop mechanistic hypotheses for small molecules. As part of the
research plan Prous Institute will use their proprietary computational methods
to predict targets for compounds used in cancer cell line small molecule
sensitivity profiling experiments, and Broad will work with Prous scientists to
quantify measures of prediction accuracy. The in silico screening technology
will also be applied to predict the mechanisms of action of compounds derived
from phenotypic profiling efforts at Broad.
Prous Institute has
developed Symmetry Global Mechanism of Action (GMoA), an in silico system to
identify the probable molecular targets and mode of
action of small molecules by screening more than 1,000 mechanisms of action
associated with therapeutic activity and safety liabilities. Symmetry GMoA is
used by scientists as a hypothesis generation tool to support drug discovery
and the detection of potential off-target liabilities.
About
Prous Institute for Biomedical Research
Prous Institute for
Biomedical Research is a research company comprised of two business units: drug
discovery and in silico technologies. Prous Institute’s drug discovery and
research unit is committed to discovering novel therapies through the
application of its proprietary drug discovery platform, Symmetry. Prous Institute’s in silico technologies unit
focuses on the research, development and commercialization of chemoinformatics
and toxicity prediction tools for drug discovery and safety screening.
Prous Institute for
Biomedical Research was founded as a spin-off from the leading scientific
information provider, Prous Science (acquired by Thomson Reuters in 2007), in
order to put into practice innovative in silico approaches to accelerate drug
discovery.
Prous Institute SymmetrySM is a predictive
analytics platform that enables hypothesis generation and elucidates the
therapeutic and safety profile of small molecules. For further information, visit the Symmetry website.
About the Broad Institute of MIT and
Harvard
The Eli and Edythe L. Broad
Institute of MIT and Harvard was launched in 2004 to empower this generation of
creative scientists to transform
medicine. The Broad Institute seeks to describe all the molecular components of
life and their connections; discover the molecular basis of major human
diseases; develop effective new approaches to diagnostics and therapeutics; and
disseminate discoveries, tools, methods and data openly to the entire
scientific community.
Founded
by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles
philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty,
professional staff and students from throughout the MIT and Harvard biomedical
research communities and beyond, with collaborations spanning over a hundred
private and public institutions in more than 40 countries worldwide. For
further information about the Broad Institute, go to http://www.broadinstitute.org.